News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Immunoassay and Infectious Disease Analyzers Evaluated during Use by Clinical Pathology Laboratories

Industrial engineering firm issues “Consumer Report”-type assessment of mid-volume, automated IA and ID analyzer systems


It’s not often that pathologists and clinical laboratory managers can access a Consumer Reports-type of comparison of laboratory analyzers as they prepare to purchase new diagnostic systems. In the case of mid-volume analyzers for immunoassy (IA) and infectious disease (ID) testing, such a report is now available—and it is immediately available on the Web.

The report is titled “Using Quality Management Methods to Compare Competing Mid-Volume Segment Immunoassay Systems that Perform Infectious Disease Testing.”  This report can be immediately downloaded and viewed by visiting the darkdaily.com web site.

(more…)

Volume of Clinical Pathology Laboratory Specimens Increases at Bio-Reference and Sonic Healthcare

Meanwhile, both Quest Diagnostics and LabCorp report second quarter declines in specimen volume


Fewer patients visiting physician offices during second quarter 2010 is considered to be one reason why specimen volume declined at clinical pathology laboratory testing giants Quest Diagnostics Incorporated (NYSE: DGX) and Laboratory Corporation of America (NYSE: LH) during that three-month period.

For second quarter, LabCorp reported a 2% decline in specimen volume, along with a 4.2% increase in revenue. At Quest Diagnostics, the specimen volume decline was 1.3% and revenues declined by 1.4% in the second quarter 2010, compared to second quarter 2009.

(more…)

AACC’s Clinical Pathology Laboratory Exhibition Showcases New Technology and Greater Interest in Lab Testing

Many new in vitro diagnostics companies show their products last week in Anaheim


It’s a troubling fact that most health policymakers in the public and private sectors continue to handle clinical pathology laboratory testing as a commodity. That often translates into health insurance programs paying medical laboratories ever less money for the tests they provide. Under-reimbursement for lab tests is a threat to the integrity of laboratory medicine in this country.

However, two groups in our country think differently than this group of health policymakers. These are patients and Wall Street investors. Individuals in both groups are closely tracking advances in laboratory testing and laboratory medicine that positively affect patient care. They know the clinical and economic benefit of using new clinical lab test technology for the right patient at the right time.

(more…)

Come 2012, Clinical Pathology Laboratories Will Need to Support Accountable Care Organizations

New Federal Mandate Will Make ACO-Based Provider Networks Responsible for Improving Quality and Cutting Costs

Pathologists and clinical laboratories are positioned to benefit from the provision in the Affordable Care Act of 2010 that is intended to reduce the cost of healthcare. It is the provision which authorizes the use of  “accountable care organizations” (ACOs) and will be triggered in 2012.

Accountable care organizations are not yet a well-defined concept. ACOs are recognized to have some basic characteristics. First, an ACO is an integrated care network of providers with the ability to provide care to, and manage patients, across the continuum of care that should include different institutional settings, such as ambulatory care, inpatient hospital care, and even post-acute care.

(more…)

Expanding Knowledge about the Human Microbiome Will Lead to New Clinical Pathology Laboratory Tests

With $175 Million in Funding, Human Microbiome Project is Making Rapid Progress

Research into the human microbiome is expected to trigger development of new diagnostic tests that will be offered by clinical pathology laboratories. That’s because the organisms that live on us and in us are as unique to individuals as their DNA, and scientists believe these microbes may be just as important to health. Which microbes and how much they matter to the host’s health are the questions a consortium of researchers involved in the Human Microbiome Project (HMP) hope to answer.

This five-year, $157-million project, funded by the National Institutes of Health, will sequence and classify 900 microbes believed to play a role in human health. Analysis of the sequences of the first 178 microbes, which was published in the May 21 issue of Science, held some surprises, particularly in regard to the extent and complexity of microbial diversity. About 90% of their DNA was previously unknown. The study also identified novel genes and proteins that contribute to human health and disease.

(more…)

;